Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2012
03/22/2012US20120070411 Substituted nucleotide analogs
03/22/2012US20120070410 Imidazolothiazole compounds and methods of use thereof
03/22/2012US20120070409 Tetracyclic fused heterocyclic compound and use thereof as hcv polymerase inhibitor
03/22/2012US20120070408 Methods and compositions for treating lupus
03/22/2012US20120070406 Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
03/22/2012US20120070405 Uses of Modified ELR-CXC Chemokine G31P To Treat Cancer
03/22/2012US20120070404 Increasing cancer patient survival time by administration of dithio-containing compounds
03/22/2012US20120070403 Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy
03/22/2012US20120070392 Composition for inhibiting erythema caused by ultraviolet radiation containing a dipeptide as active ingredient
03/22/2012US20120070390 Topical drug delivery system with dual carriers
03/22/2012US20120070386 Trehalulose-containing composition, its preparation and use
03/22/2012US20120070383 Polymeric nano-carriers with a linear dual response mechanism and uses thereof
03/22/2012US20120070370 Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
03/22/2012US20120070368 Methods of Using C-Met Modulators
03/22/2012DE19735587B4 Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens Peptide having radioprotective effect, cosmetic or pharmaceutical composition containing it, for this coding nucleic acid, production processes for this peptide and use as radioprotektives agent
03/22/2012DE102010047283B4 Untersuchungsverfahren/Screeningverfahren unter Einbeziehung von lebenden Geweben des Blutgefäß-Systems Investigation procedure / screening processes involving living tissues of the vascular system
03/22/2012CA2811538A1 Na+/mg2+ exchanger
03/22/2012CA2811295A1 Broad spectrum antibiotic arylomycin analogs
03/22/2012CA2811291A1 Treatment of chronic nephropathies using soluble complement receptor type i (scr1)
03/22/2012CA2811086A1 Step-derived peptide for brain injury treatment
03/22/2012CA2810734A1 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
03/22/2012CA2810731A1 Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
03/22/2012CA2810243A1 Formulations of guanylate cyclase c agonists and methods of use
03/21/2012EP2431480A2 Methods and compositions for increasing the stress resistance of cells and organisms
03/21/2012EP2431468A1 Interleukin-1 conjugates and uses thereof
03/21/2012EP2431390A1 Compositions and methods for modulating hemostasis
03/21/2012EP2431389A1 Compositions and methods for modulating hemostasis
03/21/2012EP2431385A2 Combination therapy with chlorotoxin
03/21/2012EP2431379A2 HCV inhibitors
03/21/2012EP2431055A1 Conjugates of membrane translocating agents and pharmaceutically active agents
03/21/2012EP2431051A1 Type-1 interferons for the treatment of multiple sclerosis
03/21/2012EP2431050A1 Methods of treating cancer using IL-21 and monoclonal antibody therapy
03/21/2012EP2431049A2 Pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, and method for treating or preventing such diseases
03/21/2012EP2431048A2 Phenolic binding peptides
03/21/2012EP2431047A1 Muscle repair promoter
03/21/2012EP2431029A2 Method of inhibiting prostate cancer cell proliferation
03/21/2012EP2430923A1 Compositions and methods for liver growth and liver protection
03/21/2012EP2430157A1 Antigen peptide and use thereof
03/21/2012EP2430044A1 Peptides increasing the secretion and/or expression of at least one gastrointestinal mucin and/or inducing an increase in the population of mucus cells or paneth cells
03/21/2012EP2430039A1 Ttk peptides and vaccines including the same
03/21/2012EP2430038A2 Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
03/21/2012EP2429585A1 Vaccine immunotherapy
03/21/2012EP2429584A2 Methods and compositions for treatment
03/21/2012EP2429583A1 Methods and compositions for treating lupus
03/21/2012EP2429580A1 Method for orthopoxvirus production and purification
03/21/2012EP2429579A1 Immortalized avian cell lines and use thereof
03/21/2012EP2429577A2 New human rotavirus strains and vaccines
03/21/2012EP2429574A1 Compositions and methods for treating hematologic cancers targeting the sirp - cd47 interaction
03/21/2012EP2429573A1 Lactoferrin and brain health and protection in adults
03/21/2012EP2429572A1 Lactoferrin and brain health and development in infants
03/21/2012EP2429571A1 Lactoferrin and neuronal health and development in the infant gut
03/21/2012EP2429570A1 Lactoferrin and gut neuronal health in adults and/or elderly
03/21/2012EP2429569A2 Treatment of eye diseases using encapsulated cells encoding and secreting a neuroprotective factor and/or an anti-angiogenic factor
03/21/2012EP2429568A1 Macrocyclic compounds as hepatitis c virus inhibitors
03/21/2012EP2429567A1 Method of labelling interferons with peg
03/21/2012EP2429566A2 Cyclin dependent kinase inhibitors and methods of use
03/21/2012EP2429565A2 Peptides and aptamers for targeting of neuron or nerves
03/21/2012EP2429564A1 Pharmaceutical compositions containing antifungal peptides
03/21/2012EP2429563A1 Peptide able to disrupt the protein complex between the his273 mutaded p53 protein and the oncosuppressive p73 protein in tumour cells and therapeutic uses thereof
03/21/2012EP2429562A1 Use of inclusion bodies as therapeutic agents
03/21/2012EP2429531A2 Use of lipid conjugates in the treatment of diseases associated with vasculature
03/21/2012EP2185588B9 Synthetic pulmonary surfactant peptides
03/21/2012EP2162463B1 Vegf-d mutants and their use
03/21/2012EP2097110B1 Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (hcn) channels
03/21/2012EP1888103B1 Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
03/21/2012EP1888101B1 Compositions and methods for lipo modeling
03/21/2012EP1734989B1 Novel use of antisecretory factor
03/21/2012EP1708755B1 Transglutaminase mediated conjugation of peptides
03/21/2012EP1656555B1 Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
03/21/2012EP1632244B1 Preventives or remedies for hepatopathy
03/21/2012EP1515988B1 Dna sequence and recombinant production of the grass pollen allergen phl p4
03/21/2012EP1506409B1 Assays for modulators of asparaginyl hydroxylase
03/21/2012EP1404412B1 Protein C for wound healing
03/21/2012EP1387854B1 Sfrp and peptide motifs that interact with sfrp and methods of their use
03/21/2012EP1320540B9 Peptidomimetic protease inhibitors
03/21/2012EP1313853B1 Modulation of fas and fasl expression by a synthetic phosphodiester oligonucleotide and an anti-fas antibody
03/21/2012EP1289533B1 Whitening compositions containing ascomycete derived enzyme
03/21/2012EP0692972B2 Method for delivering beneficial compositions to hair follicles
03/21/2012CN1980699B Treatment methods utilizing albumin-binding proteins as targets
03/21/2012CN1972706B Malignant tumor-inhibiting preparation comprising des A fibrin
03/21/2012CN1917861B Stabilised compositions of factor vii polypeptides
03/21/2012CN102388135A Protease for wound conditioning and skin care
03/21/2012CN102388062A Trail variants for treating cancer
03/21/2012CN102388060A Actagardine derivatives
03/21/2012CN102387817A Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
03/21/2012CN102387812A Methods for improving neurological outcome after neural injury and neurodegenerative disease
03/21/2012CN102387811A Use of antisecretory factors (AF) for optimizing cellular uptake
03/21/2012CN102387810A Identification of extracellular form of PTEN that can be used to treat tumors
03/21/2012CN102387809A Compositions and methods to prevent and/or treat cancer with PA -CARD
03/21/2012CN102387794A Inhibition of biofilm organisms
03/21/2012CN102387772A Oligomeric biosurfactants in dermatocosmetic compositions
03/21/2012CN102382839A Anti-herpes simplex virus (HSV) active polypeptide of Tibetan Pi scorpion and application thereof
03/21/2012CN102382806A TAT-WNK102 transmembrane protein and application thereof
03/21/2012CN102382193A Fusion protein capable of inducing and activating cancer-targeted T cells, preparation method and use thereof
03/21/2012CN102382192A Hypoallergenic recombinant immunotoxin, and preparation method and application thereof
03/21/2012CN102382191A Preparation method and application of novel braingutpeptide stimulant molecule
03/21/2012CN102382187A FBXL15 protein fragment, coding gene thereof, and application of FBXL15 protein fragment and coding gene
03/21/2012CN102382179A Peptide sequences and compositions
03/21/2012CN102382173A Oligopeptide C and antibacterial application thereof
03/21/2012CN102382172A Binding agents which inhibit myostatin
1 ... 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 ... 3163